|
Table No.
|
Table Title
|
|
Table 1.1-1
|
Patent information of flucetosulfuron in some countries/regions, as of April 2015
|
|
Table 1.1-2
|
Registration information of flucetosulfuron in China, as of April 2015
|
|
Table 1.2-1
|
Patent information of flufenpyr-ethyl in some countries/regions, as of April 2015
|
|
Table 1.3-1
|
Patent information of foramsulfuron in some countries/regions, as of April 2015
|
|
Table 1.3-2
|
Registration information of foramsulfuron in Argentina, as of April 2015
|
|
Table 1.3-3
|
Registration information of foramsulfuron in Australia, as of April 2015
|
|
Table 1.3-4
|
Registration information of foramsulfuron in Belgium, as of April 2015
|
|
Table 1.3-5
|
Registration information of foramsulfuron in Canada, as of April 2015
|
|
Table 1.3-6
|
Registration information of foramsulfuron in Chile, as of April 2015
|
|
Table 1.3-7
|
Registration information of foramsulfuron in Denmark, as of April 2015
|
|
Table 1.3-8
|
Registration information of foramsulfuron in France, as of April 2015
|
|
Table 1.3-9
|
Registration information of foramsulfuron in Greece, as of April 2015
|
|
Table 1.3-10
|
Registration information of foramsulfuron in the Netherlands, as of April 2015
|
|
Table 1.3-11
|
Registration information of foramsulfuron in Switzerland, as of April 2015
|
|
Table 1.3-12
|
Registration information of foramsulfuron in Uruguay, as of April 2015
|
|
Table 1.4-1
|
Patent information of metamifop in some countries/regions, as of April 2015
|
|
Table 1.4-2
|
Registration information of metamifop in China, as of April 2015
|
|
Table 1.5-1
|
Patent information of orthosulfamuron in some countries/regions, as of April 2015
|
|
Table 1.5-2
|
Registration information of orthosulfamuron in Brazil, as of April 2015
|
|
Table 1.5-3
|
Registration information of orthosulfamuron in China, as of April 2015
|
|
Table 1.6-1
|
Patent information of penoxsulam in some countries/regions, as of April 2015
|
|
Table 1.6-2
|
Registration information of penoxsulam in Argentina, as of April 2015
|
|
Table 1.6-3
|
Registration information of penoxsulam in Brazil, as of April 2015
|
|
Table 1.6-4
|
Registration information of penoxsulam in Chile, as of April 2015
|
|
Table 1.6-5
|
Registration information of penoxsulam in China, as of April 2015
|
|
Table 1.6-6
|
Registration information of penoxsulam in France, as of April 2015
|
|
Table 1.6-7
|
Registration information of penoxsulam in Greece, as of April 2015
|
|
Table 1.6-8
|
Registration information of penoxsulam in Switzerlands, as of April 2015
|
|
Table 1.6-9
|
Registration information of penoxsulam in Uruguay, as of April 2015
|
|
Table 1.7-1
|
Patent information of pinoxaden in some countries/regions, as of April 2015
|
|
Table 1.7-2
|
Registration information of pinoxaden in Argentina, as of April 2015
|
|
Table 1.7-3
|
Registration information of pinoxaden in Australia, as of April 2015
|
|
Table 1.7-4
|
Registration information of pinoxaden in Belgium, as of April 2015
|
|
Table 1.7-5
|
Registration information of pinoxaden in Canada, as of April 2015
|
|
Table 1.7-6
|
Registration information of pinoxaden in Chile, as of April 2015
|
|
Table 1.7-7
|
Registration information of pinoxaden in China, as of April 2015
|
|
Table 1.7-8
|
Registration information of pinoxaden in Finland, as of April 2015
|
|
Table 1.7-9
|
Registration information of pinoxaden in France, as of April 2015
|
|
Table 1.7-10
|
Registration iunformation of pinoxaden in Greece, as of April 2015
|
|
Table 1.7-11
|
Registration information of pinoxaden in the Netherlands, as of April 2015
|
|
Table 1.7-12
|
Registration information of pinoxaden in Switzerland, as of April 2015
|
|
Table 1.7-13
|
Registration information of pinoxaden in Uruguay, as of April 2015
|
|
Table 1.8-1
|
Patent information of propoxycarbazone in some countries/regions, as of April 2015
|
|
Table 1.8-2
|
Registration information of propoxycarbazone in Belgium, as of April 2015
|
|
Table 1.8-3
|
Registration information of propoxycarbazone in Finland, as of April 2015
|
|
Table 1.8-4
|
Registration information of propoxycarbazone in France, as of April 2015
|
|
Table 1.8-5
|
Registration information of propoxycarbazone in Greece, as of April 2015
|
|
Table 1.9-1
|
Patent information of tembotrione in some countries/regions, as of April 2015
|
|
Table 1.9-2
|
Registration information of tembotrione in Belgium, as of April 2015
|
|
Table 1.9-3
|
Registration information of tembotrione in Canada, as of April 2015
|
|
Table 1.9-4
|
Registration information of tembotrione in Chile, as of April 2015
|
|
Table 1.9-5
|
Registration information of tembotrione in France, as of April 2015
|
|
Table 1.9-6
|
Registration information of tembotrione in Greece, as of April 2015
|
|
Table 1.9-7
|
Registration information of tembotrione in the Netherlands, as of April 2015
|
|
Table 1.9-8
|
Registration information of tembotrione in Switzerland, as of April 2015
|
|
Table 1.10-1
|
Patent information of thiencarbazone-methyl in some countries/regions, as of April 2015
|
|
Table 1.10-2
|
Registration information of thiencarbazone-methyl in Belgium, as of April 2015
|
|
Table 1.10-3
|
Registration information of thiencarbazone-methyl in Canada, as of April 2015
|
|
Table 1.10-4
|
Registration information of thiencarbazone-methyl in France, as of April 2015
|
|
Table 1.10-5
|
Registration information of thiencarbazone-methyl in Greece, as of April 2015
|
|
Table 1.10-6
|
Registration information of thiencarbazone-methyl in Switzerland, as of April 2015
|
|
Table 1.11-1
|
Patent information of topramezone in some countries/regions, as of April 2015
|
|
Table 1.11-2
|
Registration information of topramezone in Argentina, as of April 2015
|
|
Table 1.11-3
|
Registration information of topramezone in Belgium, as of April 2015
|
|
Table 1.11-4
|
Registration information of topramezone in Canada, as of April 2015
|
|
Table 1.11-5
|
Registration information of topramezone in Chile, as of April 2015
|
|
Table 1.11-6
|
Registration information of topramezone in China, as of April 2015
|
|
Table 1.11-7
|
Registration information of topramezone in Greece, as of April 2015
|
|
Table 1.11-8
|
Registration information of topramezone in the Netherlands, as of April 2015
|
|
Table 2.1-1
|
Patent information of bistrifluron in some countries/regions, as of April 2015
|
|
Table 2.1-2
|
Registration information of bistrifluron in Australia, as of April 2015
|
|
Table 2.2-1
|
Patent information of clothianidin in some countries/regions, as of April 2015
|
|
Table 2.2-2
|
Registration information of clothianidin in Argentina, as of April 2015
|
|
Table 2.2-3
|
Registration information of clothianidin in Australia, as of April 2015
|
|
Table 2.2-4
|
Registration information of clothianidin in Belgium, as of April 2015
|
|
Table 2.2-5
|
Registration information of clothianidin in Brazil, as of April 2015
|
|
Table 2.2-6
|
Registration information of clothianidin in Canada, as of April 2015
|
|
Table 2.2-7
|
Registration information of clothianidin in China, as of April 2015
|
|
Table 2.2-8
|
Registration information of clothianidin in Finland, as of April 2015
|
|
Table 2.2-9
|
Registration information of clothianidin in Greece, as of April 2015
|
|
Table 2.2-10
|
Registration information of clothianidin in the Netherlands, as of April 2015
|
|
Table 2.2-11
|
Registration information of clothianidin in Switzerland, as of April 2015
|
|
Table 2.2-12
|
Registration information of clothianidin in Uruguay, as of April 2015
|
|
Table 2.3-1
|
Patent information of ethiprole in some countries/regions, as of April 2015
|
|
Table 2.3-2
|
Registration information of ethiprole in China, as of April 2015
|
|
Table 2.4-1
|
Patent information of flubendiamide in some countries/regions, as of April 2015
|
|
Table 2.4-2
|
Registration information of flubendiamide in Australia as of April 2015
|
|
Table 2.4-3
|
Registration information of flubendiamide in Chile as of April 2015
|
|
Table 2.4-4
|
Registration information of flubendiamide in China, as of April 2015
|
|
Table 2.4-5
|
Registration information of flubendiamide in Greece as of April 2015
|
|
Table 2.4-6
|
Registration information of flubendiamide in the Netherlands as of April 2015
|
|
Table 2.4-7
|
Registration information of flubendiamide in Uruguay as of April 2015
|
|
Table 2.5-1
|
Patent information of metofluthrin in some countries/regions, as of April 2015
|
|
Table 2.5-2
|
Registration information of metofluthrin in Australia, as of April 2015
|
|
Table 2.5-3
|
Registration information of metofluthrin in Canada, as of April 2015
|
|
Table 2.5-4
|
Registration information of metofluthrin in China, as of April 2015
|
|
Table 2.5-5
|
Registration information of metofluthrin in the Netherlands, as of April 2015
|
|
Table 2.6-1
|
Patent information of pyridalyl in some countries/regions, as of April 2015
|
|
Table 2.6-2
|
Registration information of pyridalyl in China, as of April 2015
|
|
Table 2.6-3
|
Registration information of pyridalyl in the Netherlands, as of April 2015
|
|
Table 2.7-1
|
Patent information of pyrifluquinazon in some countries/regions, as of April 2015
|
|
Table 2.8-1
|
Patent information of spirotetramat in some countries/regions, as of April 2015
|
|
Table 2.8-2
|
Registration information of spirotetramat in Australia, as of April 2015
|
|
Table 2.8-3
|
Registration information of spirotetramat in Belgium, as of April 2015
|
|
Table 2.8-4
|
Registration information of spirotetramat in Canada, as of April 2015
|
|
Table 2.8-5
|
Registration information of spirotetramat in Chile, as of April 2015
|
|
Table 2.8-6
|
Registration information of spirotetramat in China, as of April 2015
|
|
Table 2.8-7
|
Registration information of spirotetramat in France, as of April 2015
|
|
Table 2.8-8
|
Registration information of spirotetramat in Greece, as of April 2015
|
|
Table 2.8-9
|
Registration information of spirotetramat in the Netherlands, as of April 2015
|
|
Table 2.8-10
|
Registration information of spirotetramat in Switzerland, as of April 2015
|
|
Table 3.1-1
|
Patent information of amisulbrom in some countries/regions, as of April 2015
|
|
Table 3.1-2
|
Registration information of amisulbrom in Belgium, as of April 2015
|
|
Table 3.1-3
|
Registration information of amisulbrom in Finland, as of April 2015
|
|
Table 3.1-4
|
Registration information of amisulbrom in the Netherlands, as of April 2015
|
|
Table 3.1-5
|
Registration information of amisulbrom in Switzerland, as of April 2015
|
|
Table 3.2-1
|
Patent information of benalaxyl-M in some countries/regions, as of April 2015
|
|
Table 3.2-2
|
Registration information of benalaxyl-M in Australia, as of April 2015
|
|
Table 3.2-3
|
Registration information of benalaxyl-M in Belgium, as of April 2015
|
|
Table 3.2-4
|
Registration information of benalaxyl-M in Brazil, as of April 2015
|
|
Table 3.2-5
|
Registration information of benalaxyl-M in Chile, as of April 2015
|
|
Table 3.2-6
|
Registration information of benalaxyl-M in France, as of April 2015
|
|
Table 3.2-7
|
Registration information of benalaxyl-M in Greece , as of April 2015
|
|
Table 3.2-8
|
Registration information of benalaxyl-M in the Netherlands, as of April 2015
|
|
Table 3.2-9
|
Registration information of benalaxyl-M in Switzerland, as of April 2015
|
|
Table 3.3-1
|
Patent information of benthiavalicarb-isopropyl in some countries/regions, as of April 2015
|
|
Table 3.3-2
|
Registration information of Benthiavalicarb-isopropyl in Belgium, as of April 2015
|
|
Table 3.3-3
|
Registration information of Benthiavalicarb-isopropyl in Greece, as of April 2015
|
|
Table 3.3-4
|
Registration information of Benthiavalicarb-isopropyl in the Netherlands, as of April 2015
|
|
Table 3.3-5
|
Registration information of Benthiavalicarb-isopropyl in Switzerland, as of April 2015
|
|
Table 3.4-1
|
Patent information of cyflufenamid in some countries/regions, as of April 2015
|
|
Table 3.4-2
|
Registration information of cyflufenamid in Australia, as of April 2015
|
|
Table 3.4-3
|
Registration information of cyflufenamid in Belgium, as of April 2015
|
|
Table 3.4-4
|
Registration information of cyflufenamid in Greece, as of April 2015
|
|
Table 3.4-5
|
Registration information of cyflufenamid in the Netherlands, as of April 2015
|
|
Table 3.4-6
|
Registration information of cyflufenamid in Switzerland, as of April 2015
|
|
Table 3.5-1
|
Patent information of dimoxystrobin in some countries/regions, as of April 2015
|
|
Table 3.5-2
|
Registration information of dimoxystrobin in Belgium, as of April 2015
|
|
Table 3.5-3
|
Registration information of dimoxystrobin in Denmark, as of April 2015
|
|
Table 3.5-4
|
Registration information of dimoxystrobin in France, as of April 2015
|
|
Table 3.6-1
|
Patent information of fluopicolide in some countries/regions, as of April 2015
|
|
Table 3.6-2
|
Registration information of fluopicolide in Argentina, as of April 2015
|
|
Table 3.6-3
|
Registration information of fluopicolide in Belgium, as of April 2015
|
|
Table 3.6-4
|
Registration information of fluopicolide in Brazil, as of April 2015
|
|
Table 3.6-5
|
Registration information of fluopicolide in Canada, as of April 2015
|
|
Table 3.6-6
|
Registration information of fluopicolide in Chile, as of April 2015
|
|
Table 3.6-7
|
Registration information of fluopicolide in China, as of April 2015
|
|
Table 3.6-8
|
Registration information of fluopicolide in Finland, as of April 2015
|
|
Table 3.6-9
|
Registration information of fluopicolide in France, as of April 2015
|
|
Table 3.6-10
|
Registration information of fluopicolide in Greece, as of April 2015
|
|
Table 3.6-11
|
Registration information of fluopicolide in the Netherlands, as of April 2015
|
|
Table 3.6-12
|
Registration infromation of fluopicolide in Switzerland, as of April 2015
|
|
Table 3.6-13
|
Registration information of fluopicolide in Uruguay, as of April 2015
|
|
Table 3.7-1
|
Patent information of fluoxastrobin in some countries/regions, as of April 2015
|
|
Table 3.7-2
|
Registration information of fluoxastrobin in Argentina, as of April 2015
|
|
Table 3.7-3
|
Registration information of fluoxastrobin in Belgium, as of April 2015
|
|
Table 3.7-4
|
Registration information of fluoxastrobin in Canada, as of April 2015
|
|
Table 3.7-5
|
Registration information of fluoxastrobin in France, as of April 2015
|
|
Table 3.7-6
|
Registration information of fluoxastrobin in the Netherlands, as of April 2015
|
|
Table 3.7-7
|
Registration information of fluoxastrobin in Switzerland, as of April 2015
|
|
Table 3.7-8
|
Registration information of fluoxastrobin in Uruguay, as of April 2015
|
|
Table 3.8-1
|
Patent information of isotianil in some countries/regions, as of April 2015
|
|
Table 3.9-1
|
Patent information of metalaxyl-M in some countries/regions, as of April 2015
|
|
Table 3.9-2
|
Registration information of metalaxyl-M in Australia, as of April 2015
|
|
Table 3.9-3
|
Registration information of metalaxyl-M in Belgium, as of April 2015
|
|
Table 3.9-4
|
Registration information of metalaxyl-M in Brazil, as of April 2015
|
|
Table 3.9-5
|
Registration information of metalaxyl-M in Canada, as of April 2015
|
|
Table 3.9-6
|
Registration information of metalaxyl-M in China, as of April 2015
|
|
Table 3.9-7
|
Registration information of metalaxyl-M in Finland, as of April 2015
|
|
Table 3.9-8
|
Registration information of metalaxyl-M in Greece, as of April 2015
|
|
Table 3.9-9
|
Registration information of metalaxyl-M in the Netherlands, as of April 2015
|
|
Table 3.9-10
|
Registration information of metalaxyl-M in South Africa, as of April 2015
|
|
Table 3.9-11
|
Registration information of metalaxyl-M in Switzerland, as of April 2015
|
|
Table 3.10-1
|
Patent information of metrafenone in some countries/regions, as of April 2015
|
|
Table 3.10-2
|
Registration information of metrafenone in Australia, as of April 2015
|
|
Table 3.10-3
|
Registration information of metrafenone in Belgium, as of April 2015
|
|
Table 3.10-4
|
Registration information of metrafenone in Canada, as of April 2015
|
|
Table 3.10-5
|
Registration information of metrafenone in Chile, as of April 2015
|
|
Table 3.10-6
|
Registration information of metrafenone in France, as of April 2015
|
|
Table 3.10-7
|
Registration information of metrafenone in Greece, as of April 2015
|
|
Table 3.10-8
|
Registration information of metrafenone in Switzerland, as of April 2015
|
|
Table 3.11-1
|
Patent information of orysastrobin in some countries/regions, as of April 2015
|
|
Table 3.12-1
|
Patent information of penthiopyrad in some countries/regions, as of April 2015
|
|
Table 3.12-2
|
Registration information of penthiopyrad in Australia, as of April 2015
|
|
Table 3.12-3
|
Registration information of penthiopyrad in France, as of April 2015
|
|
Table 3.13-1
|
Patent information of prothioconazole in some countries/regions, as of April 2015
|
|
Table 3.13-2
|
Registration information of prothioconazole in Argentina, as of April 2015
|
|
Table 3.13-3
|
Registration information of prothioconazole in Australia, as of April 2015
|
|
Table 3.13-4
|
Registration information of prothioconazole in Brazil, as of April 2015
|
|
Table 3.13-5
|
Registration information of prothioconazole in Canada, as of April 2015
|
|
Table 3.13-6
|
Registration information of prothioconazole in Finland, as of April 2015
|
|
Table 3.13-7
|
Registration information of prothioconazole in France, as of April 2015
|
|
Table 3.13-8
|
Registration information of prothioconazole in Greece, as of April 2015
|
|
Table 3.13-9
|
Registration information of prothioconazole in Switzerland, as of April 2015
|
|
Table 3.14-1
|
Patent information of pyraclostrobin in some countries/regions, as of April 2015
|
|
Table 3.14-2
|
Registration information of pyraclostrobin in Argentina, as of April 2015
|
|
Table 3.14-3
|
Registration information of pyraclostrobin in Australia, as of April 2015
|
|
Table 3.14-4
|
Registration information of pyraclostrobin in Belgium, as of April 2015
|
|
Table 3.14-5
|
Registration information of pyraclostrobin in Canada, as of April 2015
|
|
Table 3.14-6
|
Registration information of pyraclostrobin in China, as of April 2015
|
|
Table 3.14-7
|
Registration information of pyraclostrobin in Denmark, as of April 2015
|
|
Table 3.14-8
|
Registration information of pyraclostrobin in Finland, as of April 2015
|
|
Table 3.14-9
|
Registration information of pyraclostrobin in France, as of April 2015
|
|
Table 3.14-10
|
Registration information of pyraclostrobin in Greece, as of April 2015
|
|
Table 3.14-11
|
Registration information of pyraclostrobin in the Netherlands, as of April 2015
|
|
Table 3.14-12
|
Registration information of pyraclostrobin in South Africa, as of April 2015
|
|
Table 3.14-13
|
Registration information of pyraclostrobin in Switzerland, as of April 2015
|
|
Table 3.14-14
|
Registration information of pyraclostrobin in Uruguay, as of April 2015
|
|
Table 3.15-1
|
Patent information of silthiofam in some countries/regions, as of April 2015
|
|
Table 3.15-2
|
Registration information of silthiofam in Belgium, as of April 2015
|
|
Table 3.15-3
|
Registration information of silthiofam in China, as of April 2015
|
|
Table 3.15-4
|
Registration information of silthiofam in Denmark, as of April 2015
|
|
Table 3.15-5
|
Registration information of silthiofam in France, as of April 2015
|
|
Table 3.16-1
|
Patent information of valifenalate in some countries/regions, as of April 2015
|
|
Table 3.16-2
|
Registration information of valifenalate in Belgium, as of April 2015
|
|
Table 3.16-3
|
Registration information of valifenalate in France, as of April 2015
|
|
Table 3.16-4
|
Registration information of valifenalate in Switzerland, as of April 2015
|